1. Home
  2. VATE vs BOLD Comparison

VATE vs BOLD Comparison

Compare VATE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INNOVATE Corp.

VATE

INNOVATE Corp.

HOLD

Current Price

$7.54

Market Cap

110.8M

Sector

Industrials

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.93

Market Cap

60.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VATE
BOLD
Founded
1994
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
110.8M
60.8M
IPO Year
1996
2024

Fundamental Metrics

Financial Performance
Metric
VATE
BOLD
Price
$7.54
$2.93
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
654.0K
237.9K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
$1,246,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.55
N/A
52 Week Low
$3.75
$0.96
52 Week High
$21.30
$3.16

Technical Indicators

Market Signals
Indicator
VATE
BOLD
Relative Strength Index (RSI) 42.78 69.02
Support Level $4.54 $2.71
Resistance Level $13.60 $2.97
Average True Range (ATR) 1.05 0.15
MACD 0.20 -0.00
Stochastic Oscillator 15.02 48.27

Price Performance

Historical Comparison
VATE
BOLD

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: